The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for ...

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast. Boehringer Ingelheim reported this week that its phase 3 Fibroneer-IPF trial had met ...

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...

Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have confidence and answer hard questions. She is CEO of Vaxess and wants to be able to ...

She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this position, Alison oversees project management and all teams responsible for ...

uMotif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its platform with the acquisition of ClinOne, a provider of site platform solutions ...

This complexity is being driven by various factors, including efforts to make treatments more effective and to avoid side-effects, targeting new modes of action, and improving target specificity. The ...

Lonza, a global leader in the pharmaceutical, biotech, and nutraceutical markets, has announced a significant expansion of its clinical manufacturing services at its small molecules site in Bend, ...